Science Corporation implants PRIMA chip in first Stargardt disease patient, CEO announces at TechCrunch Disrupt
Science Corporation implanted its PRIMA vision‑restoring chip in a patient with Stargardt disease, CEO Max Hodak announced on stage at TechCrunch Disrupt. The PRIMA implant is a two millimetre by two millimetre device placed at the back of the eye and PRIMA is commercially available in Europe for patients with geographic atrophy.
AI-assisted synthesis · Based on 2 independent reports from 5 outlets · Full text read from 1 of 2 reportsHow it's made
What happened
Key facts
- Max Hodak, CEO of Science Corporation, announced on stage at TechCrunch Disrupt that the company implanted its PRIMA vision‑restoring chip in a patient with Stargardt disease (per TechCrunch, ua.news, konsulteer.com).
- Hodak said the PRIMA implant is two millimetres by two millimetres and is placed under the retina at the back of the eye (per TechCrunch).
- PRIMA is commercially available in Europe for patients with geographic atrophy, an advanced form of age‑related macular degeneration (per TechCrunch).
- Approximately 150,000 people worldwide have lost vision due to Stargardt disease, according to the TechCrunch article (per TechCrunch).
- Science Corporation was founded in 2021 by Max Hodak after he left Neuralink (per TechCrunch).
The brief
Science Corporation has implanted its PRIMA vision‑restoring chip in a patient with Stargardt disease, the company’s CEO Max Hodak announced on stage at TechCrunch Disrupt. Hodak revealed the procedure during his presentation at the Disrupt conference, which the TechCrunch article notes opened its doors on Oct. 13.
The announcement was presented as a milestone for the company’s neural engineering work and its efforts to restore visual pathways from the retina to the brain. In Hodak’s account to the TechCrunch audience, the PRIMA device is a compact two millimetre by two millimetre implant positioned under the retina at the back of the eye.
He said the implant effectively creates a narrow window for sight, likening the experience to “looking through a straw.” The TechCrunch text describes PRIMA as already commercially available in Europe for patients with geographic atrophy, a severe form of age‑related macular degeneration.
The article states that roughly 150,000 people worldwide have lost vision because of Stargardt disease and frames the PRIMA implant in that patient as advancing a potential clinical path for people with that inherited retinal condition.
Hodak placed the procedure in the context of Science Corporation’s founding: he left Neuralink and started Science Corporation in 2021 with plans to pursue advanced neural engineering and brain‑computer interface technologies.
Hodak told the TechCrunch audience that the retina is part of the central nervous system and described vision as electrical activity transmitted down the optic nerve; he used that explanation to situate the PRIMA implant as a device‑based approach to restoring visual signals.
The company’s immediate clinical priorities, he said on stage, include applying its neural engineering tools to a clinical indication the company has not yet publicly named.
TechCrunch’s reporting quoted Hodak directly when describing the implant’s size, placement and the patient’s experience; beyond Hodak’s onstage remarks, the article does not provide independent clinical data, patient identity, outcome measures from the implant procedure, regulatory details beyond PRIMA’s availability in Europe for geographic atrophy, or a timeline for further clinical reporting.
Science Corporation’s implant announcement was also summarized in headline form by other outlets, including Konsulteer, mezha.net, UA.NEWS and Yahoo Tech, which echoed TechCrunch’s central claim that the company implanted PRIMA in a patient with Stargardt disease and that the news originated at TechCrunch Disrupt.
Why it matters
- Patients with Stargardt disease bear concrete costs: the TechCrunch article says about 150,000 people worldwide have lost vision from the condition, making any clinically meaningful restoration approach relevant to that defined patient population.
- Regulatory and access stakes are specified: PRIMA is already commercially available in Europe for geographic atrophy, which documents an existing market authorization pathway for at least one retinal indication.
- Clinical transparency and evidence are immediate interests: TechCrunch reports Hodak’s onstage claims but provides no independent clinical outcome data, so clinicians, regulators and patient groups have a documented need for trial results or published outcomes before assessing efficacy.
What to watch next
- Whether Science Corporation publishes clinical outcome data or peer‑reviewed results for the Stargardt patient that Hodak announced at TechCrunch Disrupt.
- Whether Science Corporation names the additional clinical indication Hodak said the company plans to apply its neural engineering tools to.
- Whether regulators or health authorities in Europe or elsewhere issue guidance or approvals related to PRIMA’s use beyond geographic atrophy.
How it's being covered
Coverage analysisShow details5 source articles · 5 unique outlets · 2 distinct reportsCoverage mix: Center Only· 4 CenterWhere the outlets are based: US/Canada 40% · Europe 40% · Other 20%
- Coverage is currently concentrated among Center-rated outlets (4 of 4 rated sources); comparatively few Left or Right-rated outlets have published on the event.
How outlets' accounts compare
How we got here
Immediate backdrop: Science Corporation was founded in 2021 by Max Hodak after he left Neuralink, establishing the company that pursued the PRIMA retinal prosthesis prior to this announcement. The specific commercial milestone cited by companies was that PRIMA was made commercially available in Europe for geographic atrophy as of 2026.
The technological lineage traces to earlier retinal prosthesis work: the first FDA approval of a retinal implant, the Argus II system, was granted in 2013, creating a regulatory and clinical precedent for implantable vision prostheses.
Original sources
2 of 5 articles · Europe · Show allEvery story links to the reporting it was built from. How we choose sources
Spotted a factual error, a broken link or a misleading summary? Tell us.